David V Gold

Summary

Affiliation: Garden State Cancer Center
Country: USA

Publications

  1. pmc Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin
    David V Gold
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Morris Plains, NJ, USA
    Mol Cancer 12:143. 2013
  2. pmc PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma
    David V Gold
    Center for Molecular Medicine and Immunology, Garden State Cancer Center, Morris Plains, NJ 07950, USA
    Cancer 119:522-8. 2013
  3. pmc Enhanced expression of CD74 in gastrointestinal cancers and benign tissues
    David V Gold
    Garden State Cancer Center, Center for Molecular Medicine and Immunology Belleville, NJ 07109, USA
    Int J Clin Exp Pathol 4:1-12. 2010
  4. ncbi request reprint Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer
    David V Gold
    Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Clin Cancer Res 9:3929S-37S. 2003
  5. ncbi request reprint Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft
    David V Gold
    Garden State Cancer Center, Center for Molecular Medicine and Immunology Belleville, NJ 07109, USA
    Int J Cancer 109:618-26. 2004
  6. ncbi request reprint A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma
    David V Gold
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey, USA
    Cancer Res 68:4819-26. 2008
  7. ncbi request reprint PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma
    David V Gold
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA
    Clin Cancer Res 13:7380-7. 2007
  8. ncbi request reprint New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis
    David V Gold
    Garden State Cancer Center at the Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA
    J Clin Oncol 24:252-8. 2006
  9. pmc Detection of early-stage pancreatic adenocarcinoma
    David V Gold
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA
    Cancer Epidemiol Biomarkers Prev 19:2786-94. 2010
  10. ncbi request reprint Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer
    Thomas M Cardillo
    The Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA
    Int J Cancer 97:386-92. 2002

Research Grants

Detail Information

Publications23

  1. pmc Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin
    David V Gold
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Morris Plains, NJ, USA
    Mol Cancer 12:143. 2013
    ..Prior results suggested the antigen is a mucin-type glycoprotein rich in cysteine disulfide bridges that provide stable conformation for the PAM4-epitope...
  2. pmc PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma
    David V Gold
    Center for Molecular Medicine and Immunology, Garden State Cancer Center, Morris Plains, NJ 07950, USA
    Cancer 119:522-8. 2013
    ..The objective of the current study was to evaluate a PAM4-based serum enzyme immunoassay alone and in combination with the carbohydrate antigen (CA) 19-9 assay for the detection of PDAC, with particular attention to early stage disease...
  3. pmc Enhanced expression of CD74 in gastrointestinal cancers and benign tissues
    David V Gold
    Garden State Cancer Center, Center for Molecular Medicine and Immunology Belleville, NJ 07109, USA
    Int J Clin Exp Pathol 4:1-12. 2010
    ....
  4. ncbi request reprint Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer
    David V Gold
    Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Clin Cancer Res 9:3929S-37S. 2003
    ....
  5. ncbi request reprint Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft
    David V Gold
    Garden State Cancer Center, Center for Molecular Medicine and Immunology Belleville, NJ 07109, USA
    Int J Cancer 109:618-26. 2004
    ..001). These data suggest that addition of (90)Y-DOTA-cPAM4 RAIT to a gemcitabine treatment regimen may provide enhanced antitumor efficacy for the treatment of pancreatic cancer...
  6. ncbi request reprint A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma
    David V Gold
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey, USA
    Cancer Res 68:4819-26. 2008
    ..Thus, the results suggest that TF10 pretargeting may provide improved imaging for early detection, diagnosis, and treatment of pancreatic cancer as compared with directly radiolabeled PAM4-IgG...
  7. ncbi request reprint PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma
    David V Gold
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA
    Clin Cancer Res 13:7380-7. 2007
    ....
  8. ncbi request reprint New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis
    David V Gold
    Garden State Cancer Center at the Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA
    J Clin Oncol 24:252-8. 2006
    ..The sensitivity and specificity of the assay are examined and compared to results from a CA19-9 immunoassay...
  9. pmc Detection of early-stage pancreatic adenocarcinoma
    David V Gold
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA
    Cancer Epidemiol Biomarkers Prev 19:2786-94. 2010
    ..Monoclonal antibody PAM4 is reactive with a unique biomarker expressed by >85% of pancreatic adenocarcinomas. In this report, we examined the ability of a PAM4-based immunoassay to detect early-stage disease...
  10. ncbi request reprint Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer
    Thomas M Cardillo
    The Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA
    Int J Cancer 97:386-92. 2002
    ..Our data show that combined gemcitabine with radioimmunotherapy may provide an improved alternative for the treatment of pancreatic cancer, achieving successful anti-tumor effects with low toxicity...
  11. ncbi request reprint Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine
    Habibe Karacay
    Center for Molecular Medicine and Immunology, Belleville, New Jersey 07109, USA
    J Nucl Med 50:2008-16. 2009
    ..The studies reported herein examine a new pretargeting procedure for delivering therapeutic radionuclides...
  12. ncbi request reprint Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy
    Thomas M Cardillo
    Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Clin Cancer Res 10:3552-61. 2004
    ..The purpose of this study was to evaluate a pretargeting method with a bispecific PAM4 (bsPAM4; anti-MUC1) antibody for radioimmunoscintigraphy of experimental human pancreatic cancer...
  13. ncbi request reprint Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell lines
    David E Modrak
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA
    Mol Cancer Res 7:890-6. 2009
    ..Our results provide further evidence that targeting the sphingolipid metabolism is a means of enhancing the efficacy of chemotherapeutic agents...
  14. pmc Horizontal transmission of malignancy: in-vivo fusion of human lymphomas with hamster stroma produces tumors retaining human genes and lymphoid pathology
    David M Goldenberg
    Center for Molecular Medicine and Immunology, Garden State Cancer Center, Morris Plains, NJ, USA
    PLoS ONE 8:e55324. 2013
    ..The B-cell gene signature of the hybrid xenografts suggests that Hodgkin lymphoma, or its initiating cells, is a B-cell malignancy...
  15. ncbi request reprint CD74 is expressed by multiple myeloma and is a promising target for therapy
    Jack D Burton
    Center for Molecular Medicine and Immunology and Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Clin Cancer Res 10:6606-11. 2004
    ..Preclinical efficacy of anti-CD74 monoclonal antibody (mAb) therapy has been demonstrated in B-lymphoma models. Because there are few validated antigenic targets in multiple myeloma, CD74 expression was examined...
  16. pmc Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry
    Chanjuan Shi
    From the Departments of Pathology, Microbiology, and Immunology Dr Shi and Surgical Oncology Dr Merchant, Vanderbilt University Medical Center, Nashville, Tennessee and the Center for Molecular Medicine and Immunology, Garden State Cancer Center, Morris Plains, New Jersey Mr Newsome and Drs Goldenberg and Gold
    Arch Pathol Lab Med 138:220-8. 2014
    ..The specificity of the PAM4 antibody is critical to the interpretation of the serum-based and immunohistochemical assays for detection of PDAC...
  17. doi request reprint Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers
    Serengulam V Govindan
    Immunomedics, Inc, Morris Plains, New Jersey, USA
    Mol Cancer Ther 12:968-78. 2013
    ....
  18. doi request reprint Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab
    Xiaochuan Chen
    Center for Molecular Medicine and Immunology, Garden State Cancer Center, Morris Plains, New Jersey 07950, USA
    Biol Blood Marrow Transplant 19:28-39. 2013
    ..These encouraging results warrant further exploration of milatuzumab as a possible new therapeutic agent for GVHD...
  19. ncbi request reprint Identification of a Mu-9 (anti-colon-specific antigen-p)-reactive peptide having homology to CA125 (MUC16)
    David E Modrak
    Garden State Cancer Center, Belleville, NJ 07109, USA
    Int J Oncol 26:1591-6. 2005
    ..In conclusion, our results indicate that the Mu-9-p16 peptide isolated through our screen identifies a peptide epitope shared by CSAp and CA125 and suggest that these proteins are related...
  20. ncbi request reprint Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer
    David E Modrak
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey 07109, USA
    Cancer Res 64:8405-10. 2004
    ..Because SM by itself is relatively nontoxic, addition of this lipid to agents that induce apoptosis may prove useful to enhance apoptosis and increase cytotoxicity in cancer cells...
  21. pmc Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells in vivo
    David M Goldenberg
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Morris Plains, NJ, USA
    Int J Cancer 131:49-58. 2012
    ....
  22. ncbi request reprint Evaluation of a non-viral vaccine in smallpox-vaccinated individuals and immunized HLA-transgenic mice
    Alice P Taylor
    Center for Molecular Medicine and Immunology Garden State Cancer Center CMMI GSCC, 300 The American Road, Morris Plains, NJ 07950, USA
    Hum Immunol 73:612-9. 2012
    ..vIL18BP, by eliciting human memory responses, is a viable antigen for inclusion in a virus-free vaccine. The immunogenicity of peptides was boosted by conjugation to L243, whether administered alone or combined...
  23. ncbi request reprint Sphingolipid targets in cancer therapy
    David E Modrak
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, 520 Belleville Avenue, Belleville, NJ 07109, USA
    Mol Cancer Ther 5:200-8. 2006
    ..This review summarizes the sphingolipid biosynthetic pathway, as it relates to the identification of important targets for drug discovery, and the development of novel agents capable of enhancing chemotherapy...

Research Grants9

  1. Detection and Diagnosis of Pancreatic Cancer
    David Gold; Fiscal Year: 2005
    ..Aim 3. To investigate whether inclusion of other mucin biomarkers can increase diagnostic accuracy through multivariate analyses. ..
  2. Detection and Diagnosis of Pancreatic Carcinoma
    David V Gold; Fiscal Year: 2010
    ....
  3. MoAbs for the Management of Pancreatic Cancer
    David Gold; Fiscal Year: 2002
    ..Finally, a PAM4IL2 fusion protein will be examined for its ability to enhance tumor uptake of a subsequently administered radiolabeled PAM4 antibody. ..
  4. MoAbs for the Management of Pancreatic Cancer
    David Gold; Fiscal Year: 2003
    ..Finally, a PAM4IL2 fusion protein will be examined for its ability to enhance tumor uptake of a subsequently administered radiolabeled PAM4 antibody. ..
  5. MoAbs for the Management of Pancreatic Cancer
    David Gold; Fiscal Year: 2005
    ..Finally, a PAM4IL2 fusion protein will be examined for its ability to enhance tumor uptake of a subsequently administered radiolabeled PAM4 antibody. ..
  6. Detection and Diagnosis of Pancreatic Cancer
    David Gold; Fiscal Year: 2007
    ..Aim 3. To investigate whether inclusion of other mucin biomarkers can increase diagnostic accuracy through multivariate analyses. ..
  7. MoAbs for the Management of Pancreatic Cancer
    David Gold; Fiscal Year: 2004
    ..Finally, a PAM4IL2 fusion protein will be examined for its ability to enhance tumor uptake of a subsequently administered radiolabeled PAM4 antibody. ..
  8. Detection and Diagnosis of Pancreatic Cancer
    David Gold; Fiscal Year: 2006
    ..Aim 3. To investigate whether inclusion of other mucin biomarkers can increase diagnostic accuracy through multivariate analyses. ..